Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Long-Term Debt Repayments (2019 - 2025)

BridgeBio Pharma's Long-Term Debt Repayments history spans 4 years, with the latest figure at $459.0 million for Q1 2025.

  • For Q1 2025, Long-Term Debt Repayments fell 3.05% year-over-year to $459.0 million; the TTM value through Jun 2025 reached $459.0 million, down 3.05%, while the annual FY2024 figure was $473.4 million, N/A changed from the prior year.
  • Long-Term Debt Repayments for Q1 2025 was $459.0 million at BridgeBio Pharma, down from $473.4 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $473.4 million in Q1 2024 and bottomed at $8000.0 in Q2 2021.
  • The 3-year median for Long-Term Debt Repayments is $282.5 million (2021), against an average of $259.6 million.
  • The largest YoY upside for Long-Term Debt Repayments was 3.05% in 2025 against a maximum downside of 3.05% in 2025.
  • A 3-year view of Long-Term Debt Repayments shows it stood at $106.0 million in 2021, then surged by 346.57% to $473.4 million in 2024, then decreased by 3.05% to $459.0 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Long-Term Debt Repayments are $459.0 million (Q1 2025), $473.4 million (Q1 2024), and $106.0 million (Q4 2021).